Literature DB >> 10418969

Comparative effects of rifabutin and rifampicin on cytochromes P450 and UDP-glucuronosyl-transferases expression in fresh and cryopreserved human hepatocytes.

B Reinach1, G de Sousa, P Dostert, R Ings, J Gugenheim, R Rahmani.   

Abstract

The aim of this study was to evaluate rifabutin (RBT) and rifampicin (RIF) capabilities in inducing various xenobiotic metabolizing enzymes such as cytochromes P450 (CYPs) and UDP-glucuronosyl-transferases (UGTs) in cultured fresh and cryopreserved human hepatocytes. Enzyme induction was assessed through the use of several diagnostic markers, i.e. testosterone, midazolam (MDZ), diazepam (DZP) and 7-ethoxyresorufin for CYP-dependent enzyme reactions; and AZT for UGT-dependent enzyme reactions. RBT concentrations (0.118, 0.708 microM) were selected according to previously published pharmacokinetic data in patients. The known CYP3A4 inducer in humans, RIF, was used as a positive control. At the concentrations used, no sign of cytotoxicity was evidenced. Both compounds were able to dose-dependently induce the overall metabolism of testosterone (approximately 2-fold for RBT, 4-fold for RIF) and the formation of the 6beta-hydroxylated-derivative (up to approximately 4-fold over control for RBT and approximately 10-fold for RIF), which is CYP3A4 dependent. The other hydroxylated metabolites (16alpha-OH and 2alpha-OH) were also enhanced. The metabolism of MDZ, which is specifically metabolized by CYP3A4 in humans, was also investigated following drug's exposure to hepatocytes. DZP one, which is governed by various CYPs, including CYP3A, was also investigated. RBT was shown to increase the biotransformation of both benzodiazepines (approximately 1.9-fold over control). Moreover, the effects of both drugs on ethoxyresorufin O-deethylase activity (EROD), which is representative of CYPIA1/2 isoforms, were tested. Results showed only a moderate induction of this marker (approximately 2-fold over control) when compared to the high effect observed after hepatocyte exposure to 3-methylcholantene (approximately 14-fold over control). Finally, the action of RBT and RIF on UGTs expression was investigated by using AZT as diagnostic substrate: glucuronides formation was not significantly affected by the two rifamycin derivatives. On the whole, exposure of fresh or cryopreserved human hepatocytes to RBT dose-dependently affected the levels of drug metabolizing enzymes in a dose-dependent manner. However, as already demonstrated by in vivo pharmacokinetic studies, its inducing properties towards CYPs, CYP3A in particular, are less pronounced than RIF.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10418969     DOI: 10.1016/s0009-2797(99)00089-7

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  17 in total

1.  Effect of cryopreservation on the properties of human endometrial stromal cells used in embryo co-culture systems.

Authors:  Ivan Bochev; Kalina Belemezova; Atanas Shterev; Stanimir Kyurkchiev
Journal:  J Assist Reprod Genet       Date:  2016-01-12       Impact factor: 3.412

Review 2.  Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials.

Authors:  W J Burman; K Gallicano; C Peloquin
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

3.  Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping.

Authors:  Bettina Link; Manuel Haschke; Nathalie Grignaschi; Michael Bodmer; Yvonne Zysset Aschmann; Markus Wenk; Stephan Krähenbühl
Journal:  Br J Clin Pharmacol       Date:  2008-04-11       Impact factor: 4.335

Review 4.  Hepatocyte cryopreservation: is it time to change the strategy?

Authors:  Xavier Stéphenne; Mustapha Najimi; Etienne M Sokal
Journal:  World J Gastroenterol       Date:  2010-01-07       Impact factor: 5.742

5.  Overcoming the effect of rifampin on the tacrolimus metabolism by itraconazole administration in an allogeneic hematopoietic stem cell transplant recipient.

Authors:  Takehiko Mori; Yoshinobu Aisa; Jun Kato; Yukinori Nakamura; Takayuki Shimizu; Shinichiro Okamoto
Journal:  Int J Hematol       Date:  2010-03-02       Impact factor: 2.490

Review 6.  Repositioning rifamycins for Mycobacterium abscessus lung disease.

Authors:  Uday S Ganapathy; Véronique Dartois; Thomas Dick
Journal:  Expert Opin Drug Discov       Date:  2019-06-14       Impact factor: 6.098

7.  Imatinib-sensitive tyrosine kinases regulate mycobacterial pathogenesis and represent therapeutic targets against tuberculosis.

Authors:  Ruth J Napier; Wasiulla Rafi; Mani Cheruvu; Kimberly R Powell; M Analise Zaunbrecher; William Bornmann; Padmini Salgame; Thomas M Shinnick; Daniel Kalman
Journal:  Cell Host Microbe       Date:  2011-11-17       Impact factor: 21.023

8.  Weight related differences in the pharmacokinetics of abacavir in HIV-infected patients.

Authors:  V Jullien; J-M Tréluyer; H Chappuy; J Dimet; E Rey; N Dupin; D Salmon; G Pons; S Urien
Journal:  Br J Clin Pharmacol       Date:  2005-02       Impact factor: 4.335

Review 9.  Current industrial practices in assessing CYP450 enzyme induction: preclinical and clinical.

Authors:  Michael Sinz; Gillian Wallace; Jasminder Sahi
Journal:  AAPS J       Date:  2008-08-07       Impact factor: 4.009

10.  Comparison of the induction profile for drug disposition proteins by typical nuclear receptor activators in human hepatic and intestinal cells.

Authors:  P Martin; R Riley; D J Back; A Owen
Journal:  Br J Pharmacol       Date:  2007-11-26       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.